1 ACUTE LYMFATISCHE LEUKEMIE GENEN PANEL Releasedate 19-10-2021

Gen	*Chromosoom regio*	*Type afwijking*	*Startpositie*	*Eindpositie*	*Bron**	*Evidence**
TAL1	1p33	rearrangements	47681961	47698007	3,5	1
STIL	1p33	Loss, translocation	47715810	47779819	5	1
PBX1	1q23.3	rearrangements	164528801	164821045	3,4	1
FHIT	3p14.2	loss	59735035	61237133	1	2
IL3	5q31.1	rearrangements	131396346	131398896	4	1
PDGFRB	5q32	loss/rearrangements	149493401	149535422	5	1
EBF1	5q33.3	loss	158122924	158526788	1	2
TLX3	5q35.1	rearrangements	170736287	170739138	3	1
MYB	6q23.3	gain	135502452	135540311	1	2
IKZF1	7p12.2	loss	50344377	50472798	1	1
CDKN2A	9p21.3	loss	21967750	21994490	1	2
CDKN2B	9p21.3	loss, CNLOH	22002902	22009312	1,2	2
PAX5	9p13.2	loss, translocatie	36833271	37034476	1	2
ABL1	9q34.12	rearrangements	133589267	133763062	3,4	1
NUP214	9q34.13	gain, transl(NUP214-ABL1)	134000980	134109091	3	1
PTEN	10q23.31	loss	89623194	89731687	1	2
BLNK	10q24.1	loss	97951454	98031333	1	2
TLX1	10q24.31	rearrangements	102891060	102897546	3	1
ADD3	10q25.1	loss	111756107	111895323	1	2
LMO2	11p13	rearrangements	33880122	33913836	3	1
RAG1	11p12	loss	36589563	36601310	1	2
RAG2	11p12	loss	36613492	36619829	1	2
KMT2A (MLL)	11q23.3	loss, rearrangement	118307204	118397539	1,3,4	1

1 ACUTE LYMFATISCHE LEUKEMIE GENEN PANEL Releasedate 19-10-2021

Gen	*Chromosoom regio*	*Type afwijking*	*Startpositie*	*Eindpositie*	*Bron**	*Evidence**
ETV6	12p13.2	loss/rearrangement	11802787	12048325	1,3,4	1
BTG1	12q21.33	loss	92534053	92539673	1	1
RB1	13q14.2	loss	48877882	49056026	1	1
NF1	17q11.2	loss	29421944	29704695	1	2
IKZF3	17q12	loss	37913967	38020441	1	2
HLF	17q22	rearrangements	53342320	53402426	3	1
TCF4	18q21.2	loss	52889562	53303224	1	2
TCF3	19p13.3	rearrangements	1609291	1652326	3,4	1
RUNX1	21q22.12	gain/loss/ rearrangements	36160097	36421595	1,3,4	2
ERG	21q22.2	loss	39739182	40033704	1	2
TMPRSS2	21q22.3	gain	42836477	42880085	1	2
BCR	22q11.23	rearrangements	23522551	23660224	3,4	1
CRLF2	Xp22.33,Yp11	Partial loss (indicatief CRLF2/P2RY8-rearrangement)	1314893	1331616	1	1
CSF2RA	Xp22.33,Yp11	Loss (indicatief CRLF2/P2RY8-rearrangement)	1387692	1428828	1	1
IL3RA	Xp22.33,Yp11	Loss (indicatief CRLF2/P2RY8-rearrangement)	1455508	1501582	1	1
P2RY8	Xp22.33,Yp11	Partial loss (indicatief CRLF2/P2RY8-rearrangement)	1581465	1656037	1	1

Bron:
1 = artikel **Schoumans** et al., Guidelines for genomic array analysis in acquired haematological neoplastic disorders, **Genes, Chromosomes&Cancer 2016**
2= artikel **O'Keefe** et al., Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies, **Blood 2010**
3= artikel **Rack** et al., European recommandations and quality assurance for cytogenomic analysis of haematological neoplasm, **Leukemia 2019**
4= WHO Classification of tumours of haematopoietic and lymphoid tissues, Swerdlow et al., revised 4th edition 2017
5= Cancer Cytogentics, Heim et al., third edition
Evidence: 1)present in WHO classification 2)recurrent (>5 cases for CNV en >2 for CNLOH in well-powered studies with expert consensus)